What is Phenomix Sciences?
Phenomix Sciences operates at the intersection of artificial intelligence and clinical diagnostics, specializing in precision obesity medicine. The company's core offering, the MyPhenome Test, integrates complex genetic, clinical, and biomarker data to categorize obesity phenotypes. This granular approach allows clinicians to move away from one-size-fits-all treatments, instead recommending therapeutic pathways tailored to the specific biological drivers of a patient's condition. By optimizing treatment outcomes and improving patient compliance, Phenomix Sciences addresses a massive, underserved market, effectively reducing the long-term economic burden of obesity-related comorbidities on the healthcare system.
How much funding has Phenomix Sciences raised?
Phenomix Sciences has raised a total of $7.8M across 2 funding rounds:
Grant
$2.3M
Series A
$5.5M
Series A (2024): $5.5M with participation from Labcorp, Dexcom, and Health2047
Grant (2024): $2.3M led by National Institutes of Health
Key Investors in Phenomix Sciences
Labcorp
A global leader in laboratory services and diagnostics, providing essential data to healthcare providers and pharmaceutical companies to facilitate informed clinical decision-making.
Dexcom
A prominent medical technology firm specializing in continuous glucose monitoring systems, focused on improving health outcomes through real-time data and innovative diabetes management solutions.
Health2047
A venture studio powered by the American Medical Association that identifies and scales transformative healthcare companies to address critical systemic challenges.
What's next for Phenomix Sciences?
With the support of its latest strategic backers, Phenomix Sciences is poised to transition into a phase of rapid commercial expansion and clinical integration. The company's roadmap likely includes scaling its diagnostic platform to reach a broader network of healthcare providers and integrating its findings into standard electronic health record systems. As the firm continues to refine its AI algorithms, it will likely seek to establish further partnerships with pharmaceutical and medical device companies to create a comprehensive ecosystem for metabolic care. The focus remains on validating the long-term efficacy of its personalized interventions, which will be essential for securing broader insurance coverage and cementing its role as a standard-of-care provider in the obesity medicine sector.
See full Phenomix Sciences company page
